Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection
| Author | Narjes Shokatpour | en |
| Author | Shahnaz Sali | en |
| Author | Batool Daneshpazhouh | en |
| Author | Masoud Mardani | en |
| Orcid | Narjes Shokatpour [0000-0003-1597-8979] | en |
| Orcid | Shahnaz Sali [0000-0001-8494-0611] | en |
| Orcid | Masoud Mardani [0000-0001-6082-072X] | en |
| Issued Date | 2020-09-09 | en |
| Abstract | Background: Treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents in patients with HCV/human immunodeficiency virus (HIV) co-infection remains controversial due to drug interactions with antiretroviral therapy (ART). Objectives: In this study, we assessed the efficacy and tolerability of daclatasvir/sofosbuvir (DCV/SOF) in patients with HIV-HCV co-infection in the real-life setting in Iran. Methods: A total of 44 patients with HCV-HIV co-infection (genotypes 1, 3, and 4) were treated with DCV/SOF±RBV (ribavirin) (dose-adjusted DCV for concomitant ART). Assessment of risk factors, sustained virologic response at 12 weeks after the end of treatment (SVR12), safety, and serum CD4 count was performed. Results: Most patients were male (95.2%). Four patients were HCV treatment-experienced cases, and 15 had cirrhosis or advanced fibrosis. The most common genotype was 3 (53.5%), followed by 1 (44.2%) and 4 (2.3%). HIV-1 RNA < 50 copies/mL and CD4 count > 250 cells/mm3 were observed in 81.8% and 79.1% of patients, respectively. The highest risk factor was a history of IV drug use (81.8%), followed by using a common syringe (77.3%) and tattooing (70.5%). All patients with or without cirrhosis (100%) completed the HCV treatment course and achieved SVR12. Also. 92.6% of patients on ART had CD4 count > 250 cells/mm3 at the end of treatment. The HCV treatment regimen was well-tolerated. Moreover, 15.9% of patients experienced adverse events (AEs), including anorexia, nausea, diarrhea, palpitations, and anxiety. No serious AEs or discontinuation due to AEs were reported. Conclusions: Our study showed excellent tolerability and efficacy of DCV/SOF±RBV in HIV-HCV co-infected patients with or without cirrhosis. | en |
| DOI | https://doi.org/10.5812/archcid.99952 | en |
| URI | https://brieflands.com/journals/archcid/articles/99952 | en |
| Keyword | Daclatasvir | en |
| Keyword | Sofosbuvir | en |
| Keyword | HIV-HCV Co-infection | en |
| Keyword | Antiretroviral Therapy | en |
| Keyword | Risk Factors | en |
| Publisher | Brieflands | en |
| Title | Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- archcid-15-3-99952.pdf
- Size:
- 146.72 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF